Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
Summary
HR6610 would mandate NADAC-based reimbursement and point-of-sale rebate passthrough for PBMs in federal employee health plans. The bill is early-stage with 32 cosponsors and bipartisan sponsorship. Direct financial impact on UNH, CI, and HUM is limited to a small book of business, but the legislation signals growing bipartisan appetite for PBM pricing reform that could expand to larger markets.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6610 mandates NADAC-based reimbursement and rebate passthrough, directly compressing PBM margins on federal employee health plans
- 2.Current early-stage status (referred to committee, no hearings) limits near-term market impact; bill has low probability of passage in the 119th Congress without further momentum
- 3.Bipartisan sponsorship, including House Oversight Committee Chairman Comer, signals growing legislative appetite for broader PBM reform that could expand to Medicare Part D or commercial insurance
- 4.Real market data shows UNH +36.34%, CI +9.35%, HUM +38.19% over the past 30 days — unrelated to this bill, driven by broader market trends
Market Implications
UNH ($368.92), CI ($291.70), and HUM ($239.61) have rallied sharply over the past 30 days — UNH up 36.34%, CI up 9.35%, and HUM up 38.19% — primarily driven by broader market tailwinds, not PBM reform sentiment. The FEHBP-specific mandate in HR6610 is too narrow to explain these moves. Investors should treat this 4/10 impact score bill as a watch item: if the Oversight Committee schedules a markup or a Senate companion bill is introduced, the bearish case for UNH, CI, and HUM strengthens considerably. The market is currently pricing in zero probability of PBM reform passage. Any legislative progress would introduce downside risk to the PBM-heavy revenue streams of these stocks.
Full Analysis
On December 11, 2025, Representative Auchincloss (D-MA) introduced HR6610, the Pharmacists Fight Back in Federal Employee Health Benefit Plans Act, with 32 cosponsors including Rep. Comer (R-KY), chairman of the House Oversight Committee. The bill was referred to the House Committee on Oversight and Government Reform and has no further action history — it remains in early legislative stages. The bill amends 5 U.S.C. §8904 to require all FEHBP health plans to mandate that their PBMs reimburse in-network pharmacies at the National Average Drug Acquisition Cost (NADAC) plus the lesser of 4% or $50, plus the state Medicaid dispensing fee. It also requires PBMs to pass 100% of manufacturer rebates through to patients at the point of sale by reducing coinsurance/copayments. There is no funding authorization — this is a regulatory mandate, not a spending bill. The three largest publicly traded PBMs — OptumRx ($UNH), Express Scripts ($CI), and Humana Pharmacy Solutions ($HUM) — administer prescription drug benefits for FEHBP plans. Under current practice, PBMs negotiate reimbursements below NADAC and retain a portion of manufacturer rebates as profit. HR6610 would eliminate both profit levers on the FEHBP book. However, FEHBP represents a small fraction of total PBM claims volume — the commercial market, Medicare Part D, and state Medicaid programs are far larger. The immediate financial impact on UNH, CI, and HUM is limited to tens-to-hundreds of millions annually — not a material earnings event for companies with $100B+ (UNH), $50B+ (CI), and $40B+ (HUM) in revenues. The real risk is precedent: bipartisan support for PBM reform, including the Oversight Committee chairman, signals that similar mandates could be proposed for Medicare Part D and commercial plans in future sessions. Over the trailing 30 days through April 30, 2026, UNH is up 36.34%, CI up 9.35%, and HUM up 38.19% — primarily driven by broader market and sector trends rather than this early-stage bill. The next legislative step is committee markup in the House Oversight Committee, which has not been scheduled. Without a Senate companion bill or committee action, the probability of passage in the 119th Congress remains low. Investors should monitor whether Chairman Comer advances the bill and whether a Senate version emerges — those events would materially increase the bearish thesis for large-cap PBMs.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Mandatory pricing: PBM must reimburse in-network pharmacies at NADAC + 4% or $50 (whichever is less) plus state Medicaid dispensing fee, and pass manufacturer rebates through to patients at point-of-sale.
Who must act
OptumRx, the PBM division of UnitedHealth Group (UNH), administering prescription drug benefits for FEHBP plans.
What happens
OptumRx loses ability to negotiate below-NADAC reimbursement rates and retain manufacturer rebates as profit on the FEHBP book of business, compressing per-claim gross margin on federal employee plans.
Stock impact
OptumRx's FEHBP segment faces direct margin compression; however FEHBP is a small fraction of Optum's total PBM revenue (majority is commercial, Medicare Part D, and state Medicaid). Near-term earnings impact is minimal unless the bill expands to other markets.
What the bill does
Mandatory pricing: PBM must reimburse in-network pharmacies at NADAC + 4% or $50 (whichever is less) plus state Medicaid dispensing fee, and pass manufacturer rebates through to patients at point-of-sale.
Who must act
Express Scripts, the PBM division of The Cigna Group (CI), administering prescription drug benefits for FEHBP plans.
What happens
Express Scripts loses ability to negotiate below-NADAC reimbursement rates and retain manufacturer rebates as profit on the FEHBP book of business, compressing per-claim gross margin on federal employee plans.
Stock impact
Express Scripts' FEHBP segment faces direct margin compression; similar to UNH, FEHBP is a small portion of Express Scripts' total book. The bill is early-stage with low immediate financial risk, but sets a legislative template that could expand to commercial and Medicare markets.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Medicare for All Act
Association Health Plans Act
Veterans’ ACCESS Act of 2025
Protecting Health Care and Lowering Costs Act of 2025
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
National Homeownership Month, 2026
This proclamation formalizes National Homeownership Month and details several ongoing or proposed policy actions: Fannie Mae and Freddie Mac are directed to purchase $200 billion in mortgage-backed securities to lower borrowing costs; an executive order bans large institutional investors from buying single-family homes; and the Administration calls on Congress to pass the 21st Century ROAD to Housing Act to make these reforms permanent. The action also reaffirms efforts to restrict taxpayer-backed loans to only law-abiding citizens, targeting fraud and illegal immigration as a means to improve housing affordability.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.